After Hours
$
109.67
Change
-0.53 -0.48%
Volume
Volume 252,394
Feb 8, 2023, 7:27 p.m.
Quotes are delayed by 20 min
Previous close
$ 111.99
$ 110.20
Change
-1.79 -1.60%
Day low
Day high
$109.75
$111.87

52 week low
52 week high
$93.25
$130.79

Market cap
$195.26B
Average volume
4.83M
P/E ratio
28.18
Rev. per Employee
$386,310
EPS
3.91
Dividend
0.51
Div yield
1.85%
Ex dividend date
1/12/23
MarketWatch News on ABT
-
Johnson & Johnson stock rises Wednesday, outperforms market
- MarketWatch Automation
-
Johnson & Johnson stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Johnson & Johnson stock outperforms competitors despite losses on the day
- MarketWatch Automation
-
Johnson & Johnson stock outperforms market despite losses on the day
- MarketWatch Automation
-
Johnson & Johnson stock rises Thursday, still underperforms market
- MarketWatch Automation
-
Johnson & Johnson stock rises Wednesday, still underperforms market
- MarketWatch Automation
-
Johnson & Johnson stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Johnson & Johnson stock falls Monday, underperforms market
- MarketWatch Automation
-
Johnson & Johnson stock outperforms competitors despite losses on the day
- MarketWatch Automation
-
Johnson & Johnson stock falls Thursday, underperforms market
- MarketWatch Automation
-
Johnson & Johnson stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Abbott Revenue Falls on Decline in Covid-Related Sales
- Emily Dattilo
-
Abbott Labs now sees 2023 adj. EPS of $4.30 to $4.50; FactSet consensus $4.41
- Ciara Linnane
-
Abbott Labs Q4 sales $10.091 bln, down 12%; FactSet consensus $9.665 bln
- Ciara Linnane
-
Abbott Labs Q4 adj. EPS $1.03; FactSet consensus 93 cents
- Ciara Linnane
-
Johnson & Johnson stock remains steady Tuesday, still outperforms market
- MarketWatch Automation
-
Johnson & Johnson stock outperforms competitors despite losses on the day
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Analysts Are Overwhelmingly Bullish on Abbott Laboratories
- MarketRealist.com
-
79% of Analysts Recommend a ‘Buy’ on Abbott Laboratories
- MarketRealist.com
-
What Analysts Recommend for Boston Scientific, Post-Q2 Results
- MarketRealist.com
Other News on ABT
-
Top 5 4th Quarter Trades of PIONEER TRUST BANK N A/OR
- GuruFocus.com
-
Brookmont Capital Management Buys 3, Sells 2 in 4th Quarter
- GuruFocus.com
-
Top 5 4th Quarter Trades of PARK NATIONAL CORP /OH/
- GuruFocus.com
-
Top 5 4th Quarter Trades of Arete Wealth Advisors, LLC
- GuruFocus.com
-
AbbVie Aims for New Drugs to Boost Sales
- Jared S. Hopkins
-
Top 5 4th Quarter Trades of Milestone Resources Group Ltd
- GuruFocus.com
-
Seascape Capital Management Buys 3, Sells 2 in 4th Quarter
- GuruFocus.com
-
Top 5 4th Quarter Trades of Riverstone Advisors, LLC
- GuruFocus.com
-
FDA Proposes Overhaul in Wake of Baby Formula Shortage
- Kristina Peterson
-
Rice Partnership, LLC Buys 1, Sells 4 in 4th Quarter
- GuruFocus.com
-
S&P 500 Falls as Investors Focus on Earnings
- Caitlin McCabe
-
Abbott Under Criminal Probe Over Baby Formula
- Liz Essley Whyte
-
Top 5 4th Quarter Trades of BURNS J W & CO INC/NY
- GuruFocus.com
-
Top 5 4th Quarter Trades of StrategIQ Financial Group, LLC
- GuruFocus.com
- Loading more headlines...
Press Releases on ABT
-
Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results
- BusinessWire - BZX
-
Abbott to Acquire Cardiovascular Systems, Inc.
- PR Newswire - PRF
-
Abbott Laboratories ABT Investment Analysis and Advice
- Stock Traders Daily
-
Indicators in Picture for Next Week
- Baystreet.ca
-
Abbott Laboratories ABT Pivots Trading Plans and Risk Controls
- Stock Traders Daily
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com